Graves病亚临床眼部改变:FUMO评分预测Graves眼病进展
该观察性研究纳入156例无Graves眼病(GO)的Graves病患者和45例非自身免疫性甲亢对照,基线行视力功能测试和眶部超声并构建FUMO评分(0-8分),24个月后评估GO发生。中高风险组发生明显GO更频繁且活动性及中重度比例更高,FUMO评分联合TRAb和FT3可可靠识别GO风险患者。
要点
- FUMO评分整合视力功能与眶部超声,可对GD患者进行GO早期风险分层
- 中高风险组(3-8分)较低风险组(0-2分)更易发生活动性及中重度GO
- TRAb水平和FUMO评分为GO最强独立预测因子,高FT3和吸烟亦增加风险
核心结论
- 亚临床眼部改变可预测Graves病患者GO的进展。
- FUMO评分联合TRAb和FT3水平能可靠识别发生明显GO的风险患者,支持用于早期风险分层。
研究设计与样本
- 观察性研究,纳入156例连续的无GO的Graves病患者,另设45例非自身免疫性甲亢患者为对照组。
- 基线行视力功能测试和眶部超声,分别赋分0-3分和0-5分,合计为FUMO评分(0-8分),分为低风险(0-2分)和中高风险(3-8分)。
- 24个月后评估GO发生、活动性和严重程度,比较两组差异。
主要发现
- 中高风险组较低风险组更频繁发生明显GO。
- 中高风险组GO更常表现为活动性和中重度。
- 多因素logistic回归显示TRAb水平和FUMO为GO最强独立预测因子,较高FT3和吸烟习惯也增加风险。
- 模型校准和区分度良好(AUC=0.84;P<.0001),阳性预测值73%,阴性预测值72%。
关键数值与推荐
- FUMO评分0-8分:低风险0-2分,中高风险3-8分。
- 模型AUC=0.84,P<.0001;阳性预测值73%,阴性预测值72%。
临床怎么用
- 对无GO的Graves病患者可基线评估视力功能和眶部超声,计算FUMO评分进行风险分层。
- 中高风险患者应加强监测,结合TRAb、FT3和吸烟状态综合评估GO风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This observational investigation aimed to assess the accuracy of a novel score in predicting the onset of overt Graves' orbitopathy (GO) in patients with Graves' disease (GD). MATERIALS AND METHODS: A total of 156 consecutive patients with GD without GO were enrolled. As control group, 45 patients with non-autoimmune hyperthyroidism were included. At baseline, an ophthalmological evaluation was performed, including (1) visual function tests and (2) orbital ultrasound. After 24 months, the occurrence of GO was assessed in all patients. RESULTS: At baseline, a score from 0 to 3 and a score from 0 to 5 were assigned based on the results of visual function tests and the results of orbital ultrasound, respectively. The scores were combined into an overall FUnctional and MOrphological risk score (FUMO score) (0-8 points), classifying patients as low risk (score 0-2) or medium-high risk (score 3-8). After 24 months, the 2 risk groups were compared for differences in (1) presence/absence of GO and (2) GO activity and severity. Patients in the medium-high risk group developed overt GO more frequently than those in the low-risk group. Additionally, GO was more frequently active and moderate-to-severe in medium-high risk patients. Multiple logistic regression showed that TRAb levels and FUMO were the strongest independent predictors of GO, with higher FT3 and smoking habit levels also conferring increased risk. The model demonstrated good calibration and discrimination (AUC = 0.84; P < .0001), with high positive (73%) and negative (72%) predictive value. CONCLUSION: Subclinical ocular alterations can predict the progression of GO in patients with GD. The FUMO score, particularly when combined with TRAb and FT3 levels, reliably identifies patients at risk of developing overt GO, supporting its use for early risk stratification.
引用
- Lanzolla G, Saba F, Corrias S, et al. Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression. J Clin Endocrinol Metab. 2026. PMID: 41628174. doi:10.1210/clinem/dgag037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。